Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart


Date Filing Description Download
08/08/18 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
08/08/18 S-8 Securities Registration: Employee Benefit Plan
08/08/18 10-Q Quarterly Report
08/03/18 4 Statement of Changes in Beneficial Ownership

Stock Quote

ACOR (Common Stock) $ 28.90 +0.55 (+1.94%) Volume: 306,163 MORE August 21, 2018

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *

Enter the code shown above.